Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets

23 Jun 2015 Evaluate

Jubilant Life Sciences, an integrated global Pharmaceuticals and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Levofloxacin Tablets, 250mg and 500mg, the generic version of Levaquin Tablets (of Ortho-McNeil), which is used for the treatment of adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.

The total market size for Levofloxacin Tablets as per IMS is $28 million per annum. As on March 31, 2015, Jubilant Life Sciences had a total of 806 filings for formulations of which 368 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe.

Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Specialty Pharmaceuticals and Life Science Ingredients.



Jubilant Pharmova Share Price

1047.55 -14.40 (-1.36%)
17-Dec-2025 14:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.90
Dr. Reddys Lab 1272.30
Cipla 1495.50
Zydus Lifesciences 917.85
Lupin 2111.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×